Close

PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results Apr 11, 2024 08:00AM
PTC Therapeutics (PTCT) Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA Mar 28, 2024 08:32AM
PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA Mar 28, 2024 08:30AM
PTC Therapeutics (PTCT) Provides Regulatory Updates Mar 19, 2024 07:31AM
PTC Therapeutics Provides Key Regulatory Updates Mar 19, 2024 07:30AM
View Older Stories

Feb 29, 2024 04:05PM PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Feb 27, 2024 05:20PM PTC Therapeutics to Participate at Upcoming Investor Conferences
Feb 22, 2024 04:30PM PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 15, 2024 08:00AM PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results
Jan 25, 2024 04:07PM PTC Therapeutics (PTCT) Reports Negative CHMP Opinion for Renewal of Conditional Marketing Authorization for Translarna
Jan 25, 2024 04:05PM CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarna™ (ataluren) Following Re-examination Procedure
Jan 8, 2024 09:26AM PTC Therapeutics (PTCT) Provides an Update on Commercial Progress and R&D Pipeline
Jan 8, 2024 09:26AM PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 42nd Annual J.P. Morgan Healthcare Conference
Jan 3, 2024 08:00AM PTC Therapeutics to Participate at 42nd Annual J.P. Morgan Healthcare Conference
Dec 14, 2023 04:30PM PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 5, 2023 04:16PM PTC Therapeutics (PTCT) Provides Updates on Translarna Regulatory Activities
Dec 5, 2023 04:15PM PTC Therapeutics Provides Updates on Translarna™ Regulatory Activities
Nov 3, 2023 04:30PM PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 26, 2023 04:05PM PTC Therapeutics Provides Corporate Update and Reports Third Quarter Financial Results
Oct 19, 2023 08:03AM PTC Therapeutics (PTCT) Announces Evrysdi Royalty Agreement with Royalty Pharma for Up To $1.5B
Oct 19, 2023 08:00AM PTC Therapeutics Announces Evrysdi® Royalty Agreement with Royalty Pharma for Up To $1.5 Billion
Oct 16, 2023 04:30PM PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2023 Financial Results 
Sep 28, 2023 04:32PM PTC Therapeutics (PTCT) Announces 25% Workforce Cut
Sep 28, 2023 04:30PM PTC Announces Further Strategic Prioritization and Associated Reduction in Workforce
Sep 15, 2023 06:00AM PTC Therapeutics' (PTCT) Translarna Receives Negative CHMP Opinion
Sep 15, 2023 06:00AM CHMP Delivers Opinion on Translarna™ for Conversion to Full Authorization
Sep 7, 2023 08:00AM PTC Therapeutics' 2023 STRIVE Awards Program Funds Initiatives Supporting the Duchenne Patient Community
Aug 30, 2023 08:00AM PTC Therapeutics to Participate at Upcoming Investor Conferences
Aug 3, 2023 04:01PM PTC Therapeutics Provides Corporate Update and Reports Second Quarter Financial Results
Jul 21, 2023 09:30AM PTC Therapeutics (PTCT) Announces CHMP Recommends Evrysdi for Babies Under Two Months Old with Spinal Muscular Atrophy
Jul 21, 2023 09:30AM CHMP Recommends Evrysdi® for Babies Under Two Months Old with Spinal Muscular Atrophy
Jul 20, 2023 08:00AM PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2023 Financial Results
Jul 19, 2023 04:30PM PTC Therapeutics Co-Founder Allan Jacobson, Ph.D., Awarded 2023 Gruber Genetics Prize
Jul 18, 2023 04:30PM PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jul 17, 2023 04:30PM PTC Therapeutics (PTCT) Appoints Experienced Healthcare Finance Strategist Pierre Gravier as Chief Financial Officer
Jul 17, 2023 04:30PM PTC Therapeutics Appoints Experienced Healthcare Finance Strategist Pierre Gravier as Chief Financial Officer
Jul 11, 2023 12:00PM PTC Therapeutics Announces Virtual Presentation on Phenylketonuria (PKU) and Sepiapterin
Jun 29, 2023 04:31PM PTC Therapeutics (PTCT) Reports Results from MIT-E Clinical Trial of Vatiquinone
Jun 29, 2023 04:30PM PTC Therapeutics Announces Results from MIT-E Clinical Trial of Vatiquinone for the Treatment of Mitochondrial Disease Associated Seizures
Jun 21, 2023 07:01AM PTC Therapeutics (PTCT) Shares Positive Interim Data from PIVOT-HD Clinical Trial in Huntington's Disease Patients
Jun 21, 2023 07:00AM PTC Therapeutics Shares Positive Interim Data from PIVOT-HD Clinical Trial in Huntington's Disease Patients
Jun 2, 2023 08:00AM PTC Therapeutics to Participate at Upcoming Investor Conferences
May 23, 2023 04:08PM PTC Therapeutics (PTCT) Vatiquinone MOVE-FA Registration-Directed Trial Did Not Meet Its Primary Endpoint
May 23, 2023 04:07PM PTC Therapeutics Announces Topline Results from Vatiquinone MOVE-FA Registration-Directed Trial
May 23, 2023 04:06PM PTC Therapeutics (PTCT) Announces Strategic Pipeline Prioritization
May 23, 2023 04:05PM PTC Therapeutics Announces Strategic Pipeline Prioritization
May 17, 2023 07:02AM PTC Therapeutics (PTCT) Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients
May 17, 2023 07:00AM PTC Therapeutics Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients
Apr 28, 2023 08:00AM PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Apr 27, 2023 04:01PM PTC Therapeutics Provides a Corporate Update and Reports First Quarter Financial Results
Apr 13, 2023 08:00AM PTC Therapeutics to Host Conference Call to Discuss First Quarter 2023 Financial Results
Mar 28, 2023 08:00AM PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Mar 24, 2023 07:31AM PTC Therapeutics (PTCT) Announces CEO Resignation
Mar 24, 2023 07:30AM Stuart Peltz, Ph.D., Rare Disease Pioneer, to Retire as Chief Executive Officer of PTC Therapeutics
Feb 21, 2023 04:05PM PTC Therapeutics Provides a Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
View Older Stories